The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
The FDA tweets this, let’s hope C7 results are smashing tumours and patients start to get wind of what is available.
“It doesn't take long for the FDA to grant an Expanded Access request. Review times are fast and a “granted” letter is usually sent within one day for both emergency and non-emergency requests. “
https://t.co/E0R4f0zisR
“or we’ll be back here again or lower in 2 years time!”
Back in a year if No LD or partnership,They will need 2 years cash to get signed off next year.
Bella
If you was on £400k a year you would drag it out.
If BP come knocking game over..
Bella read title
I said summer T/O
By then they will have AACR data and phase 2w data and if any leaks of a licence deal or a partnership game on….
We are all here now for a T/O the quicker the better for me,after last weeks shi te show by BOD.
If a major pharma wants the whole platform to improve their top line with expiring patents of their top selling drugs.
A low ball offer of £3bn which is criminally cheap, could start a bidding war.
They’ll need to start making moves soon before P2 starts.
If news starts to leak of a licence deal or a partnership it’s time to grab the popcorn.
GLA
AADi; Advenchem, Lilly Grant/Contract, Research funding.
C. Plummer,
Amgen; Servier Grant/Contract, Honoraria.
P. Loadman,
Avacta Grant/Contract, Paid consultant.
G. Lahu,
ThinkQ2 AG Employment.
Avacta Grant/Contract, Paid consultant.
H. S. Jones,
Avacta Grant/Contract, Paid consultant.
N. Kinnersley,
Avacta Grant/Contract, Paid consultant.
F. McLaughlin,
Avacta Employment.
C. Twelves,
MSD, Eisai, Daiichi-Sankyo, AstraZeneca, Pfizer, Lilly, Novartis and Gilead Grant/Contract, Travel, Advisory boards and research funding.
Abstract
Abstract is embargoed at this time.
CT188 / 16 - A Phase I trial of AVA6000, a Fibroblast Activation Protein (FAP)-released and tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors
Add to My Itinerary
April 9, 2024, 9:00 AM - 12:30 PM Section 48
Presenter/Authors
U. Banerji1, N. Cook2, A. Anthoney3, R. Plummer4, W. D. Tap5, J. T. R. Evans6, L. D. Cranmer7, C. Plummer8, P. Loadman9, G. Lahu10, H. S. Jones9, N. Kinnersley11, F. McLaughlin12, C. Twelves8;
1The Institute of Cancer Research, Sutton, Sutton, United Kingdom, 2The Christie NHS Foundation Trust, Manchester, United Kingdom, 3The University of Leeds, Leeds, United Kingdom, 4Newcastle University, Newcastle, United Kingdom, 5Memorial Sloan Kettering Cancer Center, New York, NY, 6University of Glasgow, Glasgow, United Kingdom, 7University of Washington Fred Hutchinson Cancer Center, Seattle, WA, 8University of Leeds, Leeds, United Kingdom, 9University of Bradford, Bradford, United Kingdom, 10ThinkQ2 AG, Baar, Switzerland, 11Octa Consulting Group, Harpenden, United Kingdom, 12Avacta Therapeutics, London, United Kingdom
Disclosures
U. Banerji,
Phoenix Solutions; PharmEnable; Ellipses Pharma Grant/Contract, Advisory board.
AstraZeneca; Onyx; Chugai; BTG; Verastem Grant/Contract, Research funding.
N. Cook,
Roche; RedEx Grant/Contract, Advisory boards.
AstraZeneca, Orion, F. Hoffmann-La Roche Ltd, Taiho, GSK, Novartis, Starpharma, Bayer, Eisai, UCB, RedX Pharmaceuticals, Stemline Therapeutics, LOXO-oncology, Avacta, Boehringer Ingelheim, Merck, Tar Grant/Contract, Research funding.
A. Anthoney, None.
R. Plummer,
Pierre Faber, Bayer, Novartis, BMS, Ellipses, Immunocore, Genmab, Astex Therapeutics, MSD, Nerviano, AmLo, Incyte, Cybrexa Benevolent AI and Sanofi Aventis Grant/Contract, Advisory board.
Alligator Biosciences, GSK, Onxeo, SOTIO Biotech AG, and AstraZeneca Grant/Contract, IDMC honoraria.
AstraZeneca, Novartis, Bayer, MSD and BMS Grant/Contract, Travel, Educational talks with grant/travel.
W. D. Tap,
Atropos; Certis Stock.
AmMax; Amgen; BioAtla; Boehringer Ingelheim; Cogent; Daiichi Sankyo; Deciphera; InhibRx; Servier; Per Events; PVI Grant/Contract, Research Funding/Advisory board.
J. T. R. Evans,
Ascelia, Astra Zeneca, Bayer, Bicycle Therapeutics, Bristol-Myers Squibb, Celgene, Eisai, Karus Therapeutics, Medivir, MSD, Otsuka, Roche, and Seagen Grant/Contract, Honoraria.
Astra Zeneca, Ascelia, Bayer, Bristol Myers Squibb, Celgene, Eisai, Nucana, MSD, Roche, Medivir, and United Medical Grant/Contract, Speaker fees.
Bristol-Myers Squibb; Roche; MSD; Pierre-Fabre; Celgene; Bayer Travel.
Astra Zeneca, Basilea, Bayer, Celgene, MiNa Therapeutics, Roche, Pfizer, Sierra, Lilly, Eisai, GSK, Novartis, Bicycle Therapeutics, Johnson and Johnson, CytomX, Vertex, Plexxikon, Boehringer, Athinex Grant/Contract, Clinical trial grants to institution.
L. D. Cranmer,
Blueprint Medicines Grant/Contract, Advisory board.
AADi; Advenchem, Lilly Grant/Cont
🤡 voting
"Without additional funds in excess of £20m, the Company would not have been able to progress any of its pre-clinical pipeline, which we believe will drive significant future shareholder value well beyond AVA6000.
Stop being a greedy twat and get a BP partner on board ASAP most LTH’s would like some professional help maximising this platform.
Put a stop to your silly games…
Shocking one guy on twitter lost all his investment his wife and kid, he is in a dark place other PI’s pleading with him to not do anything stupid…
Then there is Smith & Gardiner laughing in the City.
Holy grail in Cancer treatment.
What about mental health ?
They both need to go,funding could of been sorted months ago.
It’s not just PI’s, Wetherby’s Bonnie & Clyde have had over, just two weeks earlier they
RNS’s this:
Award Scheme, ordinary shares of 10p each in the Company ("Ordinary Shares") up to a value of £3,000 per employee will be issued at the prevailing middle market price at the close of business on 14 February 2024 to all eligible employees. These shares awarded will form part of the employee's remuneration package.
Imagine getting a bonus for all your hard work then your boss reduces by 50% two weeks later.
Hang your heads in shame Smith & Gardiner do the right thing and resign.
Only patients that attend MSK and Fred Hutch will know about it.
Oncologists all over USA will probably just stick to Standard dox for their patients.
That should change once data revealed at AACR…
H&L £50 min at 0.50p
What’s the max you can invest ?
Dear Avacta Retail share holders we would like to apologise for raising in the REX offer £6.8 million@ 50p for 13,600,000 shares.
When 15 months ago we could of sold 13,600,000 shares @ 95p and raised £12,920,000
Our resignations to follow.
Everyone print 2 copies and send it to them.
Keep this top of board so they know it’s coming
Dear Avacta Retail share holders we would like to apologise for raising in the REX offer £6.8 million@ 50p for 13,600,000 shares.
When 15 months ago we could of sold 13,600,000 shares @ 95p and raised £12,920,000
Our resignations to follow.
Everyone print 3 copies and send it to them.
Like AACR why all cloak and dagger,
In December we want to present at a major conference , everyone then speculates.
Why not just say we want to present at AACR in April with C7 data.
Done investors and city happy.
If the mad professor dropped the trial news from that RNS last week the SP would of bounced back above £1.20 +
But the nutty professor saved it to hide his 💩 show today…
Time to go…..
BITL,
I thought all patients were end of life.
18 months plus ….wow
With all that’s gone on today
Just trying to digest todays RNS not the sell out part but the trial info:
Can’t get my head around this
59-year-old with tumour shrinkage treated at 160 mg/m2 this is cohort 3 started July 22 finished Sep 22 are they saying he has been on the trial for 18 months ???
If true this is massive….
The starting dose for cohort 1 was 80 mg/m2 of AVA6000, which is equivalent to 54 mg/m2 of doxorubicin which is just below the standard dose for doxorubicin. The Safety Data Monitoring Committee ("SDMC") reviewed the data from cohort 1 in February 2022 and recommended that the dose be escalated to 120 mg/m2. The SDMC approved dose escalation to 120 mg/m2 in a second cohort, 160 mg/m2 in a third cohort, 200mg/m2 in a fourth cohort, 250mg/m2 in a fifth cohort, 310mg/m2 in a sixth cohort and 385mg/m2 in a seventh and final cohort.
Todays RNS
Deepening tumour shrinkage has been observed in two patients with disease predicted to have high FAP expression:
· A 59-year-old male with the diagnosis of undifferentiated pleomorphic sarcoma, treated at 160 mg/m2 on a three-weekly dosing ("Q3W"), resulted in a Partial Response with a duration of greater than 6 months and a tumour volume reduction of ~65%. Treatment is ongoing, with high FAP expression observed in the tumour tissue and a favourable PK profile with reduction in AUC which permits dosing for 7 additional cycles (~21 weeks)
RNS Number : 5475Q
Avacta Group PLC
29 June 2022
Avacta's Safety Data Monitoring Committee (SDMC), comprised of clinicians currently recruiting patients, has completed its review of the safety data from the second cohort dosed with AVA6000 at 120mg/m2 in the ongoing Phase I trial. Following this review, the SDMC has recommended that the clinical trial continues as planned and escalates to the next dose of AVA6000 at 160mg/m2.
Cohort 3 finished Sep 2022
So the 59 year old with 65% shrinkage was
160 mg/m2 on a three-weekly
was cohort 3 great news.